JP6499967B2 - 模倣ペプチド - Google Patents

模倣ペプチド Download PDF

Info

Publication number
JP6499967B2
JP6499967B2 JP2015540267A JP2015540267A JP6499967B2 JP 6499967 B2 JP6499967 B2 JP 6499967B2 JP 2015540267 A JP2015540267 A JP 2015540267A JP 2015540267 A JP2015540267 A JP 2015540267A JP 6499967 B2 JP6499967 B2 JP 6499967B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
peptide
apoa
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015540267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505514A5 (enExample
JP2016505514A (ja
Inventor
ヴュイユミエール、ニコラ
パガノ、サブリナ
アートレ、オリヴィエ
ガートナー、ユベール
テイシェイラ、プリシラ カミッロ
テイシェイラ、プリシラ カミッロ
クトラー、パウル
フェルベール、フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hopitaux Universitaires De Geneve
Original Assignee
F Hoffmann La Roche AG
Hopitaux Universitaires De Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Hopitaux Universitaires De Geneve filed Critical F Hoffmann La Roche AG
Publication of JP2016505514A publication Critical patent/JP2016505514A/ja
Publication of JP2016505514A5 publication Critical patent/JP2016505514A5/ja
Application granted granted Critical
Publication of JP6499967B2 publication Critical patent/JP6499967B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
JP2015540267A 2012-11-06 2013-11-06 模倣ペプチド Expired - Fee Related JP6499967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12191474 2012-11-06
EP12191474.1 2012-11-06
PCT/IB2013/059948 WO2014072916A1 (en) 2012-11-06 2013-11-06 Mimetic peptides

Publications (3)

Publication Number Publication Date
JP2016505514A JP2016505514A (ja) 2016-02-25
JP2016505514A5 JP2016505514A5 (enExample) 2016-12-22
JP6499967B2 true JP6499967B2 (ja) 2019-04-10

Family

ID=47115623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540267A Expired - Fee Related JP6499967B2 (ja) 2012-11-06 2013-11-06 模倣ペプチド

Country Status (11)

Country Link
US (1) US10087234B2 (enExample)
EP (1) EP2917234B1 (enExample)
JP (1) JP6499967B2 (enExample)
KR (1) KR102215175B1 (enExample)
CN (1) CN104768970B (enExample)
BR (1) BR112015010276A2 (enExample)
CA (1) CA2888657C (enExample)
ES (1) ES2859559T3 (enExample)
MX (1) MX364626B (enExample)
RU (1) RU2662973C2 (enExample)
WO (1) WO2014072916A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides
CA3096495A1 (en) * 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Lixisenatide synthesis with capping
US11560402B2 (en) 2018-04-10 2023-01-24 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
CN108948158B (zh) * 2018-07-21 2021-06-15 河南大学 四连接素模拟肽tnp及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
CA2549529A1 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
WO2007022248A2 (en) * 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
AU2008266753A1 (en) * 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
US8957026B2 (en) * 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2834657A1 (en) * 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Also Published As

Publication number Publication date
CA2888657C (en) 2022-05-03
MX2015005761A (es) 2015-08-12
KR102215175B1 (ko) 2021-02-15
RU2015121688A (ru) 2016-12-27
EP2917234B1 (en) 2020-12-02
KR20150082350A (ko) 2015-07-15
CA2888657A1 (en) 2014-05-15
BR112015010276A2 (pt) 2019-10-15
MX364626B (es) 2019-05-03
ES2859559T3 (es) 2021-10-04
RU2662973C2 (ru) 2018-07-31
EP2917234A1 (en) 2015-09-16
US10087234B2 (en) 2018-10-02
WO2014072916A1 (en) 2014-05-15
CN104768970B (zh) 2019-11-15
CN104768970A (zh) 2015-07-08
US20150291682A1 (en) 2015-10-15
JP2016505514A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
KR100881900B1 (ko) 항-오스테오폰틴 항체 및 그 용도
JP7438757B2 (ja) 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター
JP6499967B2 (ja) 模倣ペプチド
WO2011157905A1 (en) Polyclonal antibody binding to acetylated hmgb1
JP2024508312A (ja) 長時間作用型アミリン受容体アゴニスト及びその使用
Fu et al. Characterization of anti‐peptide antibodies directed against an extracellular immunogenic epitope on the human α1‐adrenergic receptor
JPH02479A (ja) ｓｎＲＮＰ−Ａ抗原及びそのフラグメント
JP4374316B2 (ja) β−アミロイドまたはその誘導体に対する抗体およびその用途
US7049403B2 (en) Insulin/IGF/relaxin family polypeptides and DNAS thereof
WO2008096905A1 (ja) 抗ｂｒａｋ（ｃｘｃｌ１４）ヒトモノクローナル抗体及びその用途
WO2000032627A1 (fr) Nouvelle substance physiologiquement active et ses procedes d'obtention et d'utilisation
JPH06157592A (ja) ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−１抗体の製造方法
WO2015021291A2 (en) Antibodies to acetylated cyclophilin and use thereof
JP4557421B2 (ja) 自己免疫疾患を治療するためのフィラグリン由来シトルリンペプチドの使用
WO2001004298A1 (fr) Nouvelle substance physiologiquement active, procede de production et utilisation
US7763716B2 (en) Antibody against NPW
KR101156992B1 (ko) 혈압 강하 활성을 가지는 펩티드
JP2005030852A (ja) 間質性肺炎診断剤およびこれを含有する間質性肺炎診断用キット
JPH04252956A (ja) タンパク質の測定方法、試薬及びキット
JP2006180704A (ja) 新規タンパクおよびその用途
WO2004037863A1 (ja) 抗体およびその用途
WO2005044846A1 (ja) アドレノメデュリン２およびその用途
JP2004159654A (ja) 抗体およびその用途
JP2001069996A (ja) 新規生理活性物質、その製造法および用途
JPWO2001004298A1 (ja) 新規生理活性物質、その製造法および用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190318

R150 Certificate of patent or registration of utility model

Ref document number: 6499967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees